Abstract #288 Efficacy of Canagliflozin 300 Mg in Overweight and Obese Type 2 Diabetes Mellitus Patients in a Real World Setting

2018 ◽  
Vol 24 ◽  
pp. 76-77
Author(s):  
Pankaj Aneja ◽  
Kunal Aneja ◽  
Gaurav Bhalla ◽  
Navneet Wadhwa
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Real World ◽  
Real World Setting

2220-PUB: Renal Outcomes Associated with Canagliflozin 100mg and with Intensification of SGLT2 Inhibitor Therapy Switching to Canagliflozin 300mg in Patients with Type 2 Diabetes Mellitus in a Real-World Setting: The Renal-WECAN Study

Diabetes ◽  
2020 ◽  
Vol 69 (Supplement 1) ◽  
pp. 2220-PUB
Author(s):  
JUAN J. GORGOJO-MARTINEZ ◽  
MANUEL A. GARGALLO-FERNANDEZ ◽  
ALBA GALDON ◽  
TERESA ANTÓN-BRAVO ◽  
MIGUEL BRITO-SANFIEL ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Real World ◽  
Sglt2 Inhibitor ◽  
Inhibitor Therapy ◽  
Renal Outcomes ◽  
Real World Setting

Characteristics and short-term outcomes of patients with type 2 diabetes mellitus treated with canagliflozin in a real-world setting

2014 ◽  
Vol 31 (1) ◽  
pp. 137-143 ◽  
Author(s):  
Erin K. Buysman ◽  
Wing Chow ◽  
Henry J. Henk ◽  
Marcia F.T. Rupnow
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Real World ◽  
Short Term ◽  
Real World Setting

Effectiveness of vildagliptin as add-on to metformin monotherapy among uncontrolled type 2 diabetes mellitus patients in a real-world setting

2017 ◽  
Vol 10 (1) ◽  
pp. 68-72 ◽  
Author(s):  
Cheli Melzer Cohen ◽  
Carla Davis ◽  
Varda Shalev ◽  
Gabriel Chodick
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Real World ◽  
Real World Setting ◽  
Metformin Monotherapy

scholarly journals Glycated Hemoglobin (Hba1c) Control In Patients with Type 2 Diabetes Mellitus (T2dm) Treated with Canagliflozin In a real-world setting

2015 ◽  
Vol 18 (3) ◽  
pp. A57 ◽  
Author(s):  
P. Lefebvre ◽  
D. Pilon ◽  
M. Robitaille ◽  
M. Lafeuille ◽  
W. Chow ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Real World ◽  
Glycated Hemoglobin ◽  
Real World Setting ◽  
Hba1c Control

scholarly journals Very low-calorie diet in patients with longstanding type 2 diabetes mellitus: a study of real-world outcomes

2021 ◽  
Author(s):  
Melanie Nana ◽  
Sacha Moore ◽  
Riyanath Loganathan ◽  
Victoria Williams ◽  
Mohammad Rahman ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Weight Loss ◽  
Type 2 Diabetes Mellitus ◽  
Real World ◽  
Very Low Calorie Diet ◽  
Low Calorie Diet ◽  
Real World Setting ◽  
Calorie Diet

Introduction: There is a paucity of evidence regarding the efficacy of a very low-calorie diet (VLCD) in the real-world setting. We evaluated outcomes in patients with type 2 diabetes mellitus (T2DM) who underwent VLCD. Methods: This retrospective observational study included all patients who had undergone VLCD from 2014 to 2017 (n=61). The VLCD consisted of an eight-week 800 kcal/day dietary restriction. Metabolic parameters and medications were recorded at baseline, immediately post-VLCD and at 6 and 12 months. Results: There was a significant reduction in weight of 9.96 kg (p<0.001) immediately post-VLCD, with net weight loss sustained to 12 months (p<0.05). There was a significant reduction in body mass index (BMI) sustained to 12 months (p<0.05). Paired HbA1c data were available for 38 patients. There was a significant reduction in HbA1c of 13.29 mmol/mol immediately post-VLCD (p<0.001), however no significant reduction was observed at 12 months (p>0.05). 78.7% patients had a reduction in T2DM medication burden post-VLCD, sustained in 44.3% of patients at 12 months. Analysis of patients with T2DM diagnosis duration >6 years demonstrated statistically significant weight loss sustained to 12 months (p<0.001). Conclusion: Our results demonstrate sustained reduction in BMI and weight, reduction in medication burden and temporary reduction in HbA1c in patients with T2DM undertaking a VLCD in the real-world setting

scholarly journals Efficacy and safety of canagliflozin 300 mg in overweight and obese type 2 diabetes mellitus patients in a real-world setting: COLOR study

2019 ◽  
Vol 23 (3) ◽  
pp. 307 ◽  
Author(s):  
Pankaj Aneja ◽  
Gaurav Bhalla ◽  
Neeti Parvesh ◽  
Kunal Aneja ◽  
Kashish Aneja
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Real World ◽  
Efficacy And Safety ◽  
Real World Setting

scholarly journals Short-term outcomes of patients with Type 2 diabetes mellitus treated with canagliflozin compared with sitagliptin in a real-world setting

2018 ◽  
Vol 59 (5) ◽  
pp. 251-256 ◽  
Author(s):  
YL Shao ◽  
KH Yee ◽  
SK, Koh ◽  
YF Wong ◽  
LY Yeoh ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Real World ◽  
Short Term ◽  
Real World Setting
Sign in / Sign up

Export Citation Format

Share Document